Roche's Oral SERD Giredestrant Fails Phase 3 persevERA Trial in First-Line Breast Cancer on March 11, 2026 giredestrant Malignant neoplasm of breast oral SERD persevERA PFS Roche (company) +
Roche's Giredestrant Fails Primary Endpoint in Phase 3 Breast Cancer Trial on March 09, 2026 Drops - Drug Form giredestrant Ibrance Malignant neoplasm of breast persevERA Phase 3 Clinical Trials Roche (company) +
Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial on December 11, 2025 Adjuvant Therapy ER-positive giredestrant HER2-negative hormone receptor-positive Hormone Therapy Malignant neoplasm of breast oral SERD Recurrence Risk Roche (company) +
Roche's Oral SERD Giredestrant Delays Early Breast Cancer Recurrence in Late-Stage Trial on November 18, 2025 Adjuvant Therapy Disease-Free Survival ER-positive giredestrant HER2-negative Malignant neoplasm of breast oral SERD Phase 3 trial recurrence prevention Roche (company) +
Roche's Giredestrant Advances Oral SERD Debate at ESMO 2025 on October 21, 2025 ER-Positive HER2-Negative Breast Cancer ESMO giredestrant oral SERD Roche (company) +
Roche Claims Its SERD Is Most Potent After Positive Breast Cancer Data Presented at ESMO 2025 on October 20, 2025 ER-positive giredestrant HER2-negative Malignant neoplasm of breast oral SERD Phase 3 Trial Progression-Free Survival Roche (company) Selective Estrogen Receptor Down Regulator +
Roche's Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial on September 23, 2025 advanced breast cancer Clinical Research ER-positive giredestrant Hormone Therapy Malignant neoplasm of breast oral SERD Phase 3 Clinical Trials Progression-Free Survival Roche (company) +